Publications en collaboration avec des chercheurs de AstraZeneca (United Kingdom) (29)

2024

  1. Final results and overall survival data from a phase II study of acalabrutinib monotherapy in patients with relapsed/refractory mantle cell lymphoma, including those with poor prognostic factors

    Haematologica

  2. Lack of awareness of systemic lupus erythematosus and its consequences in a cohort of moderate and severe patients in Spain: The LupusVoice study

    Lupus, Vol. 33, Núm. 7, pp. 663-674

  3. Prevalence of Homologous Recombination Deficiency Among Patients With Germline RAD51C/D Breast or Ovarian Cancer

    JAMA network open, Vol. 7, Núm. 4, pp. e247811

2023

  1. Clinical burden related to oral corticosteroid treatment of severe asthma in Spain: LEVANTE study

    Journal of Asthma, Vol. 60, Núm. 5, pp. 890-899

  2. Cluster Analyses From the Real-World NOVELTY Study: Six Clusters Across the Asthma-COPD Spectrum

    Journal of Allergy and Clinical Immunology: In Practice, Vol. 11, Núm. 9, pp. 2803-2811

2022

  1. The burden of mild asthma: Clinical burden and healthcare resource utilisation in the NOVELTY study

    Respiratory Medicine, Vol. 200

2021

  1. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1

    Autophagy, Vol. 17, Núm. 1, pp. 1-382

  2. In Vitro Models for Studying Respiratory Host–Pathogen Interactions

    Advanced Biology, Vol. 5, Núm. 6

  3. Real-world study in severe eosinophilic asthma patients refractory to anti-IL5 biological agents treated with benralizumab in Spain (ORBE study)

    BMC Pulmonary Medicine, Vol. 21, Núm. 1

2020

  1. ASTRIS, a large real-world study to evaluate the efficacy of osimertinib in epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer patients: Clinical characteristics and genotyping methods in a Spanish cohort

    Revista Espanola de Patologia, Vol. 53, Núm. 3, pp. 140-148

2018

  1. Characteristics of COPD Patients Managed in Respiratory Medicine Departments in Spain, According to GOLD Groups and GesEPOC Clinical Phenotypes

    Archivos de Bronconeumologia, Vol. 54, Núm. 11, pp. 559-567

  2. Clinical management and outcome of patients with advanced NSCLC carrying EGFR mutations in Spain

    BMC Cancer, Vol. 18, Núm. 1

  3. Comparison of plasma ctDNA and tissue/cytology-based techniques for the detection of EGFR mutation status in advanced NSCLC: Spanish data subset from ASSESS

    Clinical and Translational Oncology, Vol. 20, Núm. 10, pp. 1261-1267

  4. Creation of the SAQ-COPD Questionnaire to Determine Physical Activity in COPD Patients in Clinical Practice

    Archivos de Bronconeumologia, Vol. 54, Núm. 9, pp. 467-475

  5. Urine Metabolic Signatures of Multiple Environmental Pollutants in Pregnant Women: An Exposome Approach

    Environmental Science and Technology, Vol. 52, Núm. 22, pp. 13469-13480

2017

  1. Lesinurad, a Selective Uric Acid Reabsorption Inhibitor, in Combination With Febuxostat in Patients With Tophaceous Gout: Findings of a Phase III Clinical Trial

    Arthritis and Rheumatology, Vol. 69, Núm. 9, pp. 1903-1913

  2. The variability of respiratory symptoms and associated factors in COPD

    Respiratory Medicine, Vol. 129, pp. 165-172

2016

  1. 147P: Level of concordance between EGFR mutation status obtained from tissue/cytology and blood (plasma) for advanced non-small-cell lung cancer in Spain: ASSESS study

    Journal of Thoracic Oncology, Vol. 11, Núm. 4, pp. S122

  2. Computational Lexical Analysis of the Language Commonly Used to Describe Gout

    Arthritis Care and Research, Vol. 68, Núm. 6, pp. 763-768

2014

  1. Erratum to The Phosphatidyl-myo-Inositol Mannosyltransferase PimA Is Essential for Mycobacterium tuberculosis Growth In Vitro and In Vivo [Journal of Bacteriology, 196, 19, (2014) 3441-3451] DOI: 10.1128/JB.02332-14

    Journal of Bacteriology